Cancer Metabolism Company Metabomed Raises $12.5 Million

The company develops cancer-fighting drugs that specifically target the reprogrammed cancer cells’ metabolism to halt their growth

Yavne, Israel-based cancer metabolism company Metabomed Ltd. has raised a $12.5 million funding round, the company announced Thursday. The round was led by Yonjin Venture, with participation from existing investors M Ventures, Pfizer Ventures, Pontifax Venture Fund, Boehringer Ingelheim Venture Fund, and Arkin Bio Ventures. The company intends to use the funds to accelerate its drug towards clinical trials.

Dr. Simone Botti. Photo: Penny Goldschmidt.

 

Founded in 2013, the company develops cancer-fighting drugs that specifically target the reprogrammed cancer cells’ metabolism to halt their growth. The company has raised $30 million to date, according to the company’s statement.